Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;12(19):e2300260.
doi: 10.1002/adhm.202300260. Epub 2023 Mar 20.

Nanoparticle-Mediated STING Activation for Cancer Immunotherapy

Yongjuan Li  1   2 , Xinyan Li  1   2 , Jinmeng Yi  1   2 , Yongjian Cao  3 , Zhihai Qin  1   2 , Zhiyuan Zhong  4 , Weijing Yang  3
Affiliations
Review

Nanoparticle-Mediated STING Activation for Cancer Immunotherapy

Yongjuan Li et al. Adv Healthc Mater. 2023 Jul.

Abstract

As the first line of host defense against pathogenic infections, innate immunity plays a key role in antitumor immunotherapy. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) (cGAS-STING) pathway has attracted much attention because of the secretion of various proinflammatory cytokines and chemokines. Many STING agonists have been identified and applied into preclinical or clinical trials for cancer immunotherapy. However, the fast excretion, low bioavailability, nonspecificity, and adverse effects of the small molecule STING agonists limit their therapeutic efficacy and in vivo application. Nanodelivery systems with appropriate size, charge, and surface modification are capable of addressing these dilemmas. In this review, the mechanism of the cGAS-STING pathway is discussed and the STING agonists, focusing on nanoparticle-mediated STING therapy and combined therapy for cancers, are summarized. Finally, the future direction and challenges of nano-STING therapy are expounded, emphasizing the pivotal scientific problems and technical bottlenecks and hoping to provide general guidance for its clinical application.

Keywords: cGAS-STING pathway; cancer immunotherapy; combination therapy; drug delivery; nanoparticles.

PubMed Disclaimer

References

    1. a) X. Liang, L. Li, X. Li, T. He, S. Gong, S. Zhu, M. Zhang, Q. Wu, C. Gong, Theranostics 2021, 11, 6936;
    1. b) W. Song, S.-J. Song, J. Kuang, H. Yang, T. Yu, F. Yang, T. Wan, Y. Xu, S. T. Wei, M. X. Li, Y. Xiong, Y. Zhou, W. X. Qiu, ACS Nano 2022, 16, 15977;
    1. c) M. H. Spitzer, Y. Carmi, N. E. Reticker-Flynn, S. S. Kwek, D. Madhireddy, M. M. Martins, P. F. Gherardini, T. R. Prestwood, J. Chabon, S. C. Bendall, L. Fong, G. P. Nolan, E. G. Engleman, Cell 2017, 168, 487.
    1. a) Y. Zhai, C. Wang, Z. Jiang, Natl. Sci. Rev. 2018, 5, 791;
    1. b) T. Gong, L. Liu, W. Jiang, R. Zhou, Nat. Rev. Immunol. 2020, 20, 95;

Publication types